Cargando…
A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma
Uveal melanoma is a rare and aggressive malignancy and up to half of all patients will develop metastatic disease despite the effective treatment of the primary tumor. Insulin-like growth factors I/II play a fundamental role in the cell migration, proliferation, and apoptosis. IMC-A12, a mAb specifi...
Autores principales: | Mattei, Jane, Ballhausen, Alexej, Bassett, Roland, Shephard, Michael, Chattopadhyay, Chandrani, Hudgens, Courtney, Tetzlaff, Michael, Woodman, Scott, Sato, Takami, Patel, Sapna P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643799/ https://www.ncbi.nlm.nih.gov/pubmed/32976223 http://dx.doi.org/10.1097/CMR.0000000000000694 |
Ejemplares similares
-
Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients
por: Ballhausen, Alexej, et al.
Publicado: (2021) -
Simultaneous Inhibition of the HGF/MET and Erk1/2 Pathways Affect Uveal Melanoma Cell Growth and Migration
por: Chattopadhyay, Chandrani, et al.
Publicado: (2014) -
Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma
por: Chattopadhyay, Chandrani, et al.
Publicado: (2019) -
Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019) -
The Role of HGF/MET Signaling in Metastatic Uveal Melanoma
por: Tanaka, Ryota, et al.
Publicado: (2021)